2020, Peru, Covid-19 EXCESS deaths: Ivermectin EFFECT
… In Peru, an opportunity to track the efficacy of IVM with a close consideration of confounding factors was provided
… excess deaths as determined from Peruvian national health data were analyzed by state for ages ≥60
… compared with monthly summary data for excess deaths in Peru for the period 2020-2021 as published by the WHO in 2022
… Reductions in excess deaths over a period of 30 days after peak
… averaged 74% in the 10 states with the most intensive IVM use
… As determined across all 25 states correlated closely with the extent of IVM use (p<0.002)
… During four months of IVM use in 2020, before a new president of Peru restricted its use
… there was a 14-fold reduction in nationwide excess deaths
… then a 13-fold increase in the two months following the restriction of IVM use
… these trends in nationwide excess deaths align with WHO summary data for the same period in Peru
… The natural experiment … resulted in strong evidence for the drug’s effectiveness
… potential confounding factors, including effects of a social isolation mandate imposed in May 2020
… variations in the genetic makeup of the SARS-CoV-2 virus
… differences in seropositivity rates
… population densities across the 25 states
… were considered but did not appear to have significantly influenced these outcomes